返回 Agenda
Plenary Session: Patient Engagement throughout the Product Life Cycle
Session Chair(s)
Marilyne Chamoun, MSc
Senior Scientific Evaluator, Marketed Pharmaceuticals Bureau
Health Canada, Canada
Maria Anillo
Regulatory Affairs Project Manager
AstraZeneca Canada Inc., Canada
A patients’ knowledge of their condition and experience with treatments provides valuable insights for drug development and regulation. In this session, we will share perspectives and experiences from the regulator, industry and patient groups on the incorporation of patient expertise throughout the product life cycle.
Learning Objective : At the conclusion of this session, participants should be able to:
- Recognize the importance of incorporating the patient voice and experience throughout the drug development life cycle
- Discuss regulatory approaches for patient engagement
- Discuss best practices and challenges for incorporating patient experience data in drug development and regulation
Speaker(s)
The Novartis Patient Engagement Framework
Satya Rashi Khare, PhD, MBA, MSN
Novartis Pharmaceuticals Canada Inc., Canada
Canada Lead, Patient Engagement
Developing a Patient Involvement Strategy for Health Canada
Alysha Croker, PhD
Health Canada, Canada
Director, Strategic and Horizontal Policy
Patient Perspective in Engagement of Patients in Clinical Trials
Louise Binder, JD
Save Your Skin Foundation, Canada
Health Policy Consultant
Patient-Oriented Research and Patient Engagement in Clinical Trials
Stuart Nicholls, PhD
Ottawa Hospital Research Institute, Canada
Senior Clinical Research Associate & Strategy for Patient Oriented Research Faci